Introduction
Osteoarthritis (OA) is the most common arthritic disorder in adults. 1, 2 Disability and loss of function arising from OA contribute to a significant negative impact on patients' quality of life. 3 As the chronic nature of OA necessitates long-term management, the optimal pharmacological treatment should provide effective pain control and improved functional status, combined with good safety and tolerability.
First-line pharmacological treatment options for OA include simple analgesics (e.g. paracetamol), traditional nonsteroidal antiinflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) selective inhibitors. 4 -7 Traditional, nonselective NSAIDs are effective in reducing joint pain and improving function in OA patients; however, this drug class has well-documented side-effects, particularly within the gastrointestinal (GI) tract. 8 -10 COX-F Berenbaum, J Grifka, JP Brown et al.
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with traditional NSAIDs in OA combined with improved GI safety and tolerability. 11 -16 Lumiracoxib (Prexige ® , Novartis, Basel, Switzerland) is a COX-2 selective inhibitor in development for the treatment of OA, rheumatoid arthritis (RA) and acute pain. It is distinct from other COX-2 selective inhibitors in that it lacks a sulphurcontaining moiety, but rather possesses a carboxylic acid group that confers weakly acidic properties. 17 Lumiracoxib demonstrates good oral bioavailability, rapid absorption (T max 2 -3 h) with a short plasma half-life (3 -6 h), and dose-proportional, timeindependent pharmacokinetics without accumulation. 18 -21 Selectivity for COX-2 is maintained at lumiracoxib doses up to 800 mg daily. 22, 23 Consistent with COX-2 selectivity, lumiracoxib was associated with a reduced incidence of endoscopically-detected ulcers compared with traditional NSAIDs, in both healthy subjects and patients with OA or RA. 24 -27 As a possible consequence of its weakly acidic properties, lumiracoxib shows preferential distribution into inflamed tissue in animal models, an effect not seen with other COX-2 selective inhibitors tested. 28, 29 In addition, sustained concentrations of lumiracoxib are achieved in synovial fluid relative to plasma in patients with RA. 30 As such, the therapeutic effect of lumiracoxib was predicted to be longer than would be expected based on its plasma pharmacokinetics.
In response to the multiplicity of efficacy outcome measures used in OA studies (e.g. visual analogue scale [VAS] for pain; patient's global assessment of disease activity; Western Ontario and McMaster Universities [WOMAC™] Osteoarthritis Index questionnaire), the Outcome Measures in Clinical Trials (OMERACT) 3 and Osteoarthritis Research Society International (OARSI) criteria were proposed. The objective of the OMERACT-OARSI was to provide a single composite index of response to treatment that takes into account pain, patient's global assessment of disease activity and functional status. 31, 32 These criteria have been validated and were used in four of the larger lumiracoxib studies reported in this review to analyse response to treatment.
This review examines all clinical efficacy studies conducted to date that compared lumiracoxib with placebo, traditional NSAIDs or other COX-2 selective inhibitors in patients with OA.
Overview of the studies reviewed
The duration of studies reviewed varied from 1 to 52 weeks (Table 1) . 33 -39 All were multicentre, randomized, double-blind, parallelgroup studies conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki (1964 and subsequent revisions). All patients provided written informed consent. Lumiracoxib was compared with placebo and active comparators (diclofenac, celecoxib or rofecoxib).
The studies were performed in male and female patients aged ≥ 18 years with primary OA of the knee, hip or hand (as confirmed by the American College of Rheumatology [ACR] criteria) 40 -42 and requiring chronic NSAID treatment. At baseline, OA pain intensity in the target joint was generally required to be ≥ 40 mm on a 100 mm VAS. In six of the nine studies, no increase in pain (flare) from screening to baseline was necessary for study entry, in order to more closely reflect the reallife clinical situation. In the two short-term (1-week) studies, and the hand OA study, an increase in pain between screening and baseline was necessary for study entry. 38, 39 To minimize the effects of previous medications on the safety and efficacy assessments, 
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patients underwent a washout period for previous NSAIDs or analgesics prior to randomization. Patients were permitted paracetamol/acetaminophen rescue medication (recorded by investigators) and low-dose aspirin for cardiovascular prophylaxis when indicated (≤ 325 mg/day); other NSAIDs or analgesics were not permitted.
Efficacy variables included: OA pain intensity (100 mm VAS) in the target joint, where in most studies patients rated their worst pain experienced within the previous 24 h; the patient's global assessment of disease activity (100 mm VAS); the WOMAC™ questionnaire; 43 and for OA of the hand, the Australian/Canadian OA Hand Index (AUSCAN). 44 To establish efficacy further in terms of functional improvement in Phase III pivotal studies, additional prespecified analyses of response to treatment were performed using the OMERACT-OARSI criteria. 31, 32 According to these criteria, a patient is considered to have responded if he/she experiences either: i) a reduction of ≥ 50% from baseline and an absolute reduction of ≥ 20 either in OA pain intensity (100 mm VAS) or WOMAC™ Difficulty in Performing Daily Activities (DPDA) subscale score (rescaled to 0 -100); or ii) a reduction of ≥ 20% from baseline and an absolute reduction of ≥ 10 in at least two of the following variables: OA pain intensity (100 mm VAS), WOMAC™ DPDA subscale score (rescaled to 0 -100) or patient's global assessment of disease activity (100 mm VAS).
STATISTICAL ANALYSES
Efficacy analyses were performed on the intent-to-treat (ITT) population and a last observation carried forward approach was used to account for missing data. The ITT population included all patients randomized to treatment who received at least one dose of study medication.
In the majority of studies, primary efficacy variables were analysed using an analysis of covariance model fitting baseline value, centre and treatment group. Betweentreatment pairwise comparisons were performed using least-square means (LSMs) obtained from the model. Secondary efficacy variables were analysed similarly. In the 13-week studies and the 52-week extension study, response to treatment according to OMERACT-OARSI criteria was analysed by visit using a multiple logistic regression model with country, treatment group and baseline OA pain (100 mm VAS) as explanatory variables.
4-week studies
Two randomized, double-blind, placebocontrolled, parallel-group, multicentre, 4-week studies were conducted (Table 1) . 33, 34 In both studies, patients underwent a 3 -7-day washout period for previous NSAIDS/analgesics and were required to have a baseline pain intensity ≥ 40 mm in the affected target joint (assessed using a 100 mm VAS).
DOSE-RANGING STUDY
The dose-ranging study compared the efficacy of four doses of lumiracoxib with placebo and diclofenac in 583 patients with OA of the knee or hip. 33 Patients were randomized in the ratio 1:1:1:1:1:1 to lumiracoxib 50 mg twice daily (n = 98), 100 mg twice daily (n = 96), 200 mg twice daily (n = 99) or 400 mg once daily (n = 99), placebo (n = 97) or diclofenac 75 mg twice daily (n = 94) for 4 weeks. OA pain intensity (100 mm VAS) in the most severely affected joint was assessed at week 4 as the primary efficacy variable. In addition, patient's global assessment of disease activity (100 mm VAS) was determined at week 4.
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All doses of lumiracoxib were significantly superior to placebo and comparable with diclofenac 75 mg twice daily in reducing pain intensity in the target joint at week 4 (study end). Treatment-placebo differences in LSMs at week 4 were -18.0 mm for lumiracoxib 50 mg twice daily, -17.4 mm for lumiracoxib 100 mg twice daily, -19.1 mm for lumiracoxib 200 mg twice daily and -23.0 mm for lumiracoxib 400 mg once daily (all P ≤ 0.001 versus placebo). Mean changes from baseline to week 4 and treatment-placebo comparisons are shown in Table 2 .
With regard to patient's global assessment of disease activity, all doses of lumiracoxib were significantly superior to placebo and similar to diclofenac at week 4. Treatment -placebo differences (LSMs) at week 4 were -9.6 mm for lumiracoxib 50 mg twice daily, -12.9 mm for lumiracoxib 100 mg twice daily, -13.6 mm for lumiracoxib 200 mg twice daily, -14.3 mm for lumiracoxib 400 mg once daily and -12.9 mm for diclofenac 75 mg twice daily (all P ≤ 0.001 versus placebo).
LUMIRACOXIB 100 MG STUDY
A 4-week placebo-controlled study was conducted in 244 patients with primary OA of the hip or knee. 34 Patients were randomized in the ratio 1:1 to receive lumiracoxib 100 mg once daily (n = 122) or placebo (n = 122) for 4 weeks. OA pain intensity (100 mm VAS) in the target joint was assessed after 4 weeks of treatment as a primary efficacy variable and at 1 and 2 weeks as secondary variables. Patient's global assessment of disease activity (100 mm VAS) and functional status (using the WOMAC™ total score) were assessed at week 4.
Lumiracoxib 100 mg once daily was effective in reducing OA pain intensity in the target joint, with efficacy significantly superior to placebo after 4 weeks' treatment. The treatment-placebo difference in LSM at
TABLE 2:
Change from baseline to study end in osteoarthritis (OA) pain intensity in the 4-week studies of the efficacy of lumiracoxib in OA discussed in this review 33, 34 
Change from baseline in OA pain intensity (100 mm P-value (treatment Treatment group VAS); mean ± SD versus placebo) a
Dose-ranging study 33 Lumiracoxib 50 mg bid (n = 96) -28 
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week 4 was -8.4 mm (P = 0.003). Lumiracoxib 100 mg once daily was also superior to placebo in terms of OA pain intensity at earlier timepoints (weeks 1 and 2; both P < 0.05 versus placebo). Mean changes from baseline to week 4 and P-values for treatment-placebo comparisons are shown in Table 2 . Lumiracoxib 100 mg once daily was also superior to placebo at week 4 in terms of patient's global assessment of disease activity (mean [SD] change from baseline: -22.3 [23.12] mm; treatment-placebo difference in LSM at week 4 of -8.8 mm; P = 0.001). Functional status, assessed in terms of the WOMAC™ total score, was significantly improved with lumiracoxib 100 mg once daily compared with placebo (treatment-placebo difference in LSM at week 4 of -4.5; P = 0.021).
13-week studies
Three randomized, double-blind, placebocontrolled, active-comparator, parallelgroup, multinational, 13-week Phase III studies were conducted to compare lumiracoxib 200 mg once daily and/or 400 mg once daily with placebo and celecoxib 200 mg once daily or rofecoxib 25 mg once daily in patients with OA of the knee or hip (Table 1) . 35, 36 In each of the three studies, patients underwent an NSAID washout period of 3 -7 days and were required to have pain intensity ≥ 40 mm on a 100 mm VAS at baseline. Four co-primary efficacy variables were analysed: OA pain intensity (100 mm VAS) in the target joint, patient's global assessment of disease activity (100 mm VAS), and WOMAC™ total score and pain subscale after 13 weeks of treatment. Variables were also analysed at a secondary level by visits as follows: weeks 2, 4 and 8 for OA pain intensity in the target joint and patient's global assessment of disease activity, and week 2 or week 4 (OA of the knee or OA of the hip, respectively) for the WOMAC™ total and pain subscale scores. In addition, WOMAC™ DPDA and stiffness subscale scores were analysed at study end. At week 2 and week 13 in patients with OA of the knee and week 4 and week 13 in patients with OA of the hip, the proportion of patients responding according to OMERACT-OARSI criteria was assessed in order to confirm efficacy further.
OSTEOARTHRITIS OF THE KNEE
A pooled analysis was performed using data from the two 13-week studies comparing lumiracoxib with placebo and celecoxib in patients with OA of the knee. 35, 36 Both studies recruited patients with primary OA of the knee as confirmed by the ACR criteria. The total randomized patient population comprised 3302 patients (lumiracoxib 200 mg once daily = 949; lumiracoxib 400 mg once daily = 954; placebo = 474; celecoxib 200 mg once daily = 925).
Lumiracoxib 200 mg and 400 mg once daily and celecoxib 200 mg once daily were superior to placebo in terms of OA pain intensity in the target joint, patient's global assessment of disease activity and the WOMAC™ total score and pain subscale at all timepoints including week 13 (all P < 0.001 versus placebo). Estimated differences in LSMs between lumiracoxib 200 mg once daily and 400 mg once daily, and placebo at week 13 were: -6.8 mm and -8.4 mm, respectively, for OA pain intensity in the target joint; -8.0 mm and -9.1 mm for patient's global assessment of disease activity; -6.1 and -6.3, respectively, for the WOMAC™ total score; and -1.1 and -1.2, respectively, for the WOMAC™ pain subscale (all P < 0.001 versus placebo).
Mean changes from baseline to week 13 and P-values for treatment-placebo comparisons for all co-primary efficacy variables are shown in Table 3 . No significant differences were observed between lumiracoxib doses in The WOMAC™ DPDA and stiffness subscale scores indicated that both doses of lumiracoxib provided improvements that were superior to placebo at study end (all P < 0.001). In addition, no significant differences were observed between lumiracoxib doses, or between either dose and celecoxib.
A significantly greater proportion of patients receiving lumiracoxib 200 mg or 400 mg once daily demonstrated a response to treatment as assessed using OMERACT-OARSI criteria at week 2 and week 13 compared with placebo (P < 0.001, Fig. 1A ). No significant differences were observed between lumiracoxib doses in terms of OMERACT-OARSI responder rates at either timepoint. The two doses of lumiracoxib were also found to be similar to celecoxib in terms of this variable at both timepoints.
OSTEOARTHRITIS OF THE HIP
In the third 13-week Phase III study, 511 adult patients with primary OA of the hip as confirmed by the ACR criteria were randomized to receive lumiracoxib 400 mg once daily (n = 207), placebo (n = 204) or rofecoxib 25 mg once daily (n = 102, Novartis Pharma AG, Basel, Switzerland; unpublished data, 2002).
At week 13, lumiracoxib 400 mg once daily provided superior relief from OA pain and improvement in functional status compared with placebo, assessed via OA pain intensity in the target joint, patient's global assessment of disease activity and the WOMAC™ total score. Estimated differences between lumiracoxib 400 mg once daily and placebo in LSMs were -6.4 mm for OA pain intensity in the target joint (P = 0.007), -7.0 mm for patient's global assessment of disease activity (P = 0.003) and -3.2 for the WOMAC™ total score (P = 0.036). Numerical superiority was observed for the WOMAC™ pain subscale score at week 13 (estimated treatment-placebo difference in LSM: -0.65; P = 0.077). No significant differences were observed between lumiracoxib 400 mg once daily and rofecoxib 25 mg once daily in OA pain intensity in the target joint, patient's global assessment of disease activity, and the WOMAC™ total and pain subscale scores at week 13. Table 3 shows mean changes from baseline to week 13 and P-values for treatment-placebo comparisons in all coprimary efficacy variables.
When looking at OA pain intensity in the target joint compared with placebo at individual timepoints throughout the study, lumiracoxib 400 mg once daily demonstrated a significant reduction at the first assessment timepoint (week 2) and at all other study visits (all P < 0.01). Similar results were observed for the patient's global assessment of disease activity; superiority for lumiracoxib 400 mg once daily versus placebo was observed at all study visits (all P < 0.01). The WOMAC™ total and pain subscale scores demonstrate significant improvements versus placebo at week 4 (both P < 0.001). In general, no statistically significant differences were observed between lumiracoxib 400 mg once daily and rofecoxib 25 mg once daily in coprimary efficacy variables. Change from baseline to study end in osteoarthritis (OA) pain intensity in the target joint, patient's global assessment of disease activity and WOMAC™ total and pain subscale scores in the 13-week studies described in this review of the efficacy of lumiracoxib in OA 35, 36 
OA pain intensity in
Patient's global the target joint assessment of the disease WOMAC™ WOMAC™ pain (100 mm VAS) activity (100 mm VAS) total score subscale score 
P-value P-value P-value P-value

Efficacy of lumiracoxib in osteoarthritis
Lumiracoxib 400 mg provided significant improvements in the WOMAC™ DPDA and stiffness subscale scores which were superior to placebo (both P < 0.05) and similar to rofecoxib. Lumiracoxib 400 mg once daily was also associated with a significantly greater proportion of patients responding according to OMERACT-OARSI criteria than placebo (P < 0.05, Fig. 1B) . No significant differences were detected between lumiracoxib 400 mg once daily and rofecoxib 25 mg once daily at either timepoint in terms of OMERACT-OARSI responder rates.
52-week study
To investigate the long-term efficacy of lumiracoxib, an international, randomized, double-blind, 39-week extension phase of one of the 13-week Phase III studies 36 was performed. 37 Lumiracoxib 200 mg and 400 mg once daily were compared with celecoxib 200 mg once daily in patients with primary OA of the knee (Table 1) . 37 During the 13-week Phase III (core) study, 1702 patients were randomized to receive lumiracoxib 200 mg once daily (n = 487) or 400 mg once daily (n = 491), placebo (n = 243) or celecoxib 200 mg once daily (n = 481).
Of the 1423 patients who completed the core study, 1235 (86.6%) consented to participate in the 39-week extension phase and 1229 patients were included in the efficacy analysis. Six patients did not meet the extension efficacy analysis inclusion requirement of at least one dose of study drug in the extension phase and the provision of efficacy data in the extension phase. Those patients who received active treatment in the core study continued to receive the same active treatment for the 39-week extension phase (efficacy population = 1058). Patients receiving placebo during the core study were randomized (1:1:1) to receive lumiracoxib 200 mg once daily, lumiracoxib 400 mg once daily or celecoxib 200 mg once daily in the 39-week extension phase (efficacy population = 171 patients).
In total, 411 patients received lumiracoxib 200 mg once daily, 419 received lumiracoxib 400 mg once daily and 405 received celecoxib 200 mg once daily during the extension phase. Of these, 56, 59 and 56 patients in the lumiracoxib 200 mg oncedaily, 400 mg once-daily and celecoxib 200 mg once-daily groups, respectively, had received placebo during the core study.
The co-primary efficacy variables (OA pain intensity [100 mm VAS] in the target joint, patient's global assessment of disease activity [100 mm VAS], WOMAC™ total score and pain subscale) assessed in the core study were also analysed in the extension phase. In addition, WOMAC™ DPDA and stiffness subscale scores were analysed at study end (52 weeks). OMERACT-OARSI criteria were used to assess response at study end in patients who received active treatment throughout the study. Results are presented separately for patients who received active treatment throughout the study and patients who received placebo in the core study.
PATIENTS WHO RECEIVED ACTIVE TREATMENT THROUGHOUT
The improvements in OA pain intensity in the target joint in patients receiving lumiracoxib in the core study were maintained during the extension phase (Fig. 2) . Similar results were observed for other co-primary efficacy variables; improvements observed with lumiracoxib in the core study relating to the patient's global assessment of disease activity and functional status, assessed according to the WOMAC™ total score and pain subscale, were maintained during the extension phase. Mean changes from baseline (week 0 of core study) to the end of the extension phase (week 52) F Berenbaum, J Grifka, JP Brown et al.
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for all co-primary efficacy variables are shown in Table 4 .
In all treatment groups, the improvements in WOMAC™ DPDA and stiffness subscale scores observed in the core study were maintained during the extension phase. Mean changes from baseline (week 0 of core study) to the end of the extension phase (week 52) (SD) in the DPDA subscale score were -11.1 (12.62) for lumiracoxib 200 mg once daily, -11.5 (13.85) for lumiracoxib 400 mg once daily and -10. At week 52, similar proportions of patients in each treatment group responded to treatment according to OMERACT-OARSI criteria (66.2% in the lumiracoxib 200 mg once daily group; 69.8% in the lumiracoxib 400 mg once daily group; and 71.8% in the celecoxib 200 mg once daily group). No significant differences were observed between treatment groups. 
PATIENTS WHO RECEIVED PLACEBO IN THE CORE STUDY
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once daily during the 9 months of the extension phase. In addition, improvements in the WOMAC™ total score and pain subscale were seen in all active treatment groups. Mean changes from baseline (week 13 of core study) to week 52 (end of extension phase, after 39 weeks of active treatment) for all co-primary efficacy variables are shown in Table 4 . All treatments were also associated with improvements in functional status assessed using the WOMAC™ DPDA and stiffness subscale scores (data not shown).
DISCONTINUATION DUE TO INSUFFICIENT THERAPEUTIC EFFECT
A Kaplan-Meier analysis of time to study drug discontinuation due to insufficient therapeutic effect was carried out for all the patients in the extension phase. Over the combined study period, the percentage of patients discontinuing for this reason was 6.6% in the lumiracoxib 200 mg once daily group, 6.2% in the lumiracoxib 400 mg once daily group, and 8.3% in the celecoxib 200 mg once daily group.
Short-term studies
A new model looking at the onset of analgesia in OA was used in two short-term studies to investigate further the onset of pain relief associated with lumiracoxib 38 (Novartis Pharma AG, data on file, 2003). Both studies recruited patients with primary OA of the knee who had pain intensity in the target knee of ≥ 40 mm on a 100 mm VAS at screening and ≥ 50 mm at baseline (following a 2 -7-day NSAID washout). Unlike the other OA studies in the programme (Table 1) , pain assessments were performed after walking 20 paces on a flat surface, and an increase in pain from screening to baseline was required. The primary objective of these studies was to assess the analgesic effectiveness of the first dose of lumiracoxib compared with placebo and celecoxib, determined using the pain intensity difference (PID) between baseline and actual pain (assessed as the mean of 3-and 5-h assessments after dosing on the first day of treatment). Patients rated actual pain intensity since the last dose of study drug and immediately prior to the next dose (morning and evening). This contrasted with other lumiracoxib OA studies, where patients rated their worst pain experienced within the previous 24 h.
In the first study, 364 patients were randomized to receive lumiracoxib 400 mg once daily (n = 144), placebo (n = 75) or celecoxib 200 mg twice daily (n = 145) for 7 days. 38 Lumiracoxib 400 mg demonstrated superior pain relief compared with placebo in terms of the PID; estimated treatmentplacebo difference in LSM of -5.8 mm (P = 0.004) while celecoxib 200 mg failed to reach significance (P = 0.069). No significant difference was observed between lumiracoxib 400 mg and celecoxib 200 mg. Mean PID from baseline to the mean of 3-and 5-h assessments is shown in Table 5 .
In the second study, 408 patients were randomized to receive lumiracoxib 200 mg once daily (n = 105), lumiracoxib 400 mg once daily (n = 99), placebo (n = 103) or celecoxib 200 mg twice daily (n = 101) for 7 days (Novartis Pharma AG, data on file, 2003). Although lumiracoxib 200 mg and 400 mg once daily and celecoxib 200 mg twice daily demonstrated a numerical difference versus placebo in terms of the PID from baseline to the mean of 3-and 5-h assessments, the comparisons were not statistically significant for any of the active treatments. Estimated differences in LSMs versus placebo favoured active treatments for these comparisons: 
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Mean PID from baseline to the mean of 3and 5-h assessments is shown in Table 5 .
Osteoarthritis of the hand
Osteoarthritis of the hand differs in its clinical presentation and possibly in its pathophysiology from other types of OA. 41, 45 A multicentre, randomized, double-blind, parallel-group 4-week study was, therefore, conducted to compare lumiracoxib 200 mg and 400 mg once daily with placebo in 594 patients. 39 Patients with symptomatic OA underwent an NSAID washout period during which an increase in OA pain intensity (either ≥ 20% or ≥ 10 mm VAS, whichever was greater) was necessary to participate in the study. Eligible patients were randomized to receive lumiracoxib 200 mg once daily (n = 205), lumiracoxib 400 mg once daily (n = 193) or placebo (n = 196). In addition to evaluating overall OA pain intensity in the target hand (100 mm VAS; week 2 and week 4), patient's functional status was assessed using the AUSCAN total score. AUSCAN is a validated, self-administered questionnaire developed to assess the functional status of the hand during the previous 48 h. 44 It is based on five-point Likert scales and consists of 15 questions grouped into three sections (pain, DPDA and stiffness). At study end, lumiracoxib 200 mg and 400 mg once daily were significantly superior to placebo in terms of overall OA pain intensity in the target hand: treatmentplacebo differences in LSMs of -9.9 mm and -10.2 mm for lumiracoxib 200 mg and 400 mg once daily, respectively, both P < 0.001; and in the AUSCAN total score treatment-placebo differences in LSMs were -3.1 (P = 0.003) and -4.6 (P < 0.001), respectively (Fig. 3 ). In addition, no differences were observed between doses. Mean changes from baseline to week 4 and Pvalues for treatment-placebo comparisons are shown in Table 6 . Significance versus placebo was also observed for both lumiracoxib doses at week 2 (treatment-placebo differences in LSMs of -9.6 mm and -8.4 mm for lumiracoxib 200 mg and 400 mg once daily, respectively; both P < 0.001). 
Discussion
In this review we have presented nine studies describing the efficacy of lumiracoxib in OA of different joints. Across the studies, lumiracoxib provided significant pain relief and improvements in patient's global assessment of disease activity and functional status. In addition to providing superior efficacy compared with placebo, lumiracoxib was found to be generally similar to the active comparators tested, including the COX-2 selective inhibitors celecoxib and rofecoxib. These data demonstrate the efficacy of lumiracoxib doses of 100 -400 mg daily in OA. In those studies where lumiracoxib 200 mg daily was compared with lumiracoxib 400 mg daily, it is notable that no significant differences were observed in the efficacy variables assessed. It would appear, therefore, that there is no benefit in using 400 mg over 200 mg once daily in the clinical setting. Furthermore, although assessed in different studies, the reductions in pain intensity observed with lumiracoxib 100 mg daily and 200 mg daily from baseline to week 4 of treatment were consistent (-24.6 mm for 100 mg daily and -23.6 mm for 200 mg daily after 4 weeks' treatment). The patient's global assessment of disease activity also improved by a similar amount with lumiracoxib 100 mg daily and lumiracoxib 200 mg daily (changes of -22.3 mm and -21.3 mm, respectively, from baseline to 4 weeks). Therefore, lumiracoxib 100 mg and 200 mg are both effective daily doses. The reductions in pain intensity and improvements in patient's global assessment of disease activity with lumiracoxib 200 mg daily were maintained for the duration of the 13-week trials.
The effects of lumiracoxib on patients' pain, as indicated by assessment of OA pain intensity in the target joint and patient's global assessment of disease activity, were significant in all the studies performed and were detectable from the first time of assessment (generally week 1 or week 2) through to study completion (up to 52 weeks).
In addition to pain, functional status is an important aspect of OA. As such, the significant improvements in the WOMAC™ and AUSCAN total scores seen with lumiracoxib provide further support for using lumiracoxib in OA. While these results are significant, it is also important to assess whether they can be considered clinically meaningful. According to a recent proposed definition, the minimal difference perceived by 75% of patients (MDP75) can be regarded as representing a clinically meaningful difference. In a study sample of 1354 patients with hip and knee OA, the MDP75 for the WOMAC™ DPDA subscale score was 5.2. 46 In the 52-week study reported here, mean changes from baseline to 52 weeks were similar for the lumiracoxib 200 mg once daily and 400 mg once daily doses (11.1 and 11.5, respectively). 37 These results are similar to those seen with celecoxib in the study reported here (10.8) and in a previous study in patients with OA (change of 9.5 from baseline after treatment for 12 weeks with celecoxib 200 mg daily). 47 The OMERACT-OARSI criteria are designed to provide a single measure of clinically relevant efficacy encompassing OA pain, functional status and patient's global assessment of disease activity. 31, 32 In the studies where these criteria were applied, lumiracoxib was consistently associated with a significantly higher proportion of responders than placebo, confirming the efficacy of lumiracoxib in terms of different measures of OA symptoms. Lumiracoxib was also similar to all active comparators tested.
The symptoms of OA and their effects on functional abilities differ with other types of OA. 33 -35 As such, it was considered important to establish the efficacy of lumiracoxib across different types of OA. The studies carried out in patients with OA of the hand, hip and knee described here demonstrate the consistent, superior efficacy of lumiracoxib compared with placebo. Results from the long-term efficacy study show that the pain relief and improved functional status provided by lumiracoxib can be sustained over a prolonged period (up to 52 weeks). Given the chronic nature of OA, this is an important finding.
The scope of this review is limited to describing only the efficacy of lumiracoxib in OA. It is important to note, however, that lumiracoxib has also demonstrated a favourable tolerability profile in patients with OA. 26, 48 Compared with the traditional NSAID ibuprofen, lumiracoxib was associated with fewer endoscopically detected ulcers in a 13-week study involving 1042 patients with primary OA. 26 Furthermore, in a pooled analysis of OA and RA studies, lumiracoxib demonstrated an overall GI safety and tolerability profile superior to nonselective NSAIDs (diclofenac, naproxen and ibuprofen) and similar to other COX-2 selective inhibitors (celecoxib and rofecoxib). 48 This analysis also found that patients receiving lumiracoxib had a lower rate of upper GI symptomatic ulcers and ulcer complications (perforations, obstructions and bleeds) than patients receiving nonselective NSAIDs. 48 Also of note, lumiracoxib was associated with a markedly lower incidence of prespecified GI adverse events (AEs), symptomatic ulcers and discontinuations due to GI AEs than nonselective NSAIDs. 48 Large, longterm, randomized outcomes studies, such as the Celecoxib Long term Assessment of Safety Study (CLASS), 49 and the Vioxx ® In GI Outcomes Research (VIGOR) 50 are conducted to assess the long-term safety and tolerability of COX-2 selective inhibitors. As such, the safety and tolerability of lumiracoxib is being further investigated in the largest GI outcomes study conducted to date with a COX-2 selective inhibitor in patients with OA. The Therapeutic Arthritis Research and GI Event Trial (TARGET) of lumiracoxib versus naproxen and ibuprofen is a 52-week study comparing the GI and cardiovascular safety and tolerability of these agents in more than 18 000 patients with OA. 51 It should enable robust conclusions to be drawn regarding the safety of lumiracoxib versus two traditional NSAIDs in the clinical setting.
A further analysis of safety was performed using data from the 52-week study of lumiracoxib in OA to assess the effects of lumiracoxib on articular cartilage. 52 Radiographic monitoring of joint space width (JSW) narrowing showed no significant difference between lumiracoxib and celecoxib. For both compounds, changes in JSW narrowing were in the range reported for natural OA disease progression, demonstrating that lumiracoxib has no deleterious effect on cartilage as measured by joint space narrowing. In summary, the studies described in this review demonstrate that, in OA affecting several different joints, lumiracoxib 100 mg and 200 mg daily doses can provide effective pain relief together with improvements in function and patient's global assessment of disease activity. Lumiracoxib, a novel COX-2 selective inhibitor, is therefore an effective therapy for managing OA. 
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